Accuhaler dry powder inhaler is commonly used in the treatment of bronchial asthma and chronic obstructive pulmonary disease. The correct use of these instruments is crucial to successful treatment.

Inhaler metered dose inhaler is a familiar form of medicine to patients with respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease,... However, the proportion of patients using this inhaler correctly is still low. (About one-third of people using metered-dose inhalers do it the wrong way), leading to reduced effectiveness.

Turbuhaler dry powder inhaler is commonly indicated in the treatment of Asthma and Chronic Obstructive Pulmonary Disease. Like other instruments, the correct use of these instruments is crucial to successful treatment.

Sorbutuss medicine, scientifically known as Guaifenesin - Oral, is used to treat persistent cough and obstructive pulmonary disease caused by the common cold, bronchitis and other respiratory diseases. This product should not normally be used for persistent coughs caused by smoking or for prolonged breathing problems (such as chronic bronchitis, emphysema) unless directed by your doctor. The following article will provide information about the uses, indications and notes when using Sorbutuss.

Anticholinergics are a type of medicine that block the bad action of a neurotransmitter called acetylcholine. Before using anticholinergic drugs, patients need to know how to use them safely and effectively.

Symbicort 60 has the main ingredients Budesonide, Formoterol fumarate. Symbicort is indicated in the treatment of asthma and chronic obstructive pulmonary disease. Learn how to use Symbicort in the article below.

Breezhaler inhalers are commonly prescribed as maintenance therapy to relieve symptoms and reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with tobacco smoking that represents a significant economic burden on the global health care system. COPD affects both developed and developing countries. In 2010, the number of COPD cases worldwide was approximately 384 million, representing a prevalence of 11.7%. COPD is predicted to become the third leading cause of death by 2020.